Analysts on Tuesday peppered Centene executives with a string of queries about MA, a sector facing notable turbulence from shifting regulations and elevated medical costs. The bombardment prompted an ...

Centene (CNC) and Oscar Health (OSCR) were among notable gainers in the managed care space on Monday after Barclays upgraded ...

Centene downgraded its 2024 adjusted earnings per share target this week to greater than $6.60, reflecting its view of Medicaid redeterminations, its Medicare bid strategy and business investments, ...

Centene raised its 2023 outlook on Tuesday after the health insurer handily beat Wall Street expectations for earnings and revenue in its third quarter, helped by lower medical costs. Centene reported ...

Truist lowered the firm’s price target on Centene (CNC) to $45 from $47 and keeps a Buy rating on the shares. While there ...

Centene's top brass said Tuesday that the proposed Medicare Advantage rates for 2025 fall short of what's needed. The Centers for Medicare & Medicaid Services issued its annual Advance Notice proposal ...

Centene Corporation’s CNC Medicare brand, Wellcare, announced expansion endeavors for growth of its Medicare Advantage (MA) and Medicare Prescription Drug Plan (PDP) in 2024. Next year, Centene aims ...

Centene has a 10-year price return of 313.77%, almost double the 179.34% price return of the S&P 500. The company is strategically positioned in the market, and the current favorable trends serve as ...